-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The prognosis of chronic myeloid leukemia (CML) has improved significantly since the introduction of tyrosine kinase inhibitor (TKI) therapy
.
Few studies have reported the efficacy of tyrosine kinase inhibitors (TKIs), including the second-generation TKIs nilotinib and dasatinib, in adolescents and young adults (AYA) with chronic phase chronic myeloid leukemia (CML-CP) Therefore, a research team retrospectively analyzed the clinical characteristics and outcomes of AYA patients with CML-CP treated with TKIs, and further evaluated the outcomes of AYA patients treated with nilotinib and dasatinib
.
.
Few studies have reported the efficacy of tyrosine kinase inhibitors (TKIs), including the second-generation TKIs nilotinib and dasatinib, in adolescents and young adults (AYA) with chronic phase chronic myeloid leukemia (CML-CP) Therefore, a research team retrospectively analyzed the clinical characteristics and outcomes of AYA patients with CML-CP treated with TKIs, and further evaluated the outcomes of AYA patients treated with nilotinib and dasatinib
.
The researchers retrospectively analyzed the clinical characteristics, treatment response, and long-term outcomes of 42 AYA patients and older patients
.
Initial treatments for AYA patients between 2001 and 2016 included imatinib (n = 24), dasatinib (n = 13), and nilotinib (n = 5)
.
.
Initial treatments for AYA patients between 2001 and 2016 included imatinib (n = 24), dasatinib (n = 13), and nilotinib (n = 5)
.
42
Figure 1: Molecular responses to TKIs according to age group
.
p: level of significance between AYA and the elderly group
.
MMR: major molecular response; DMR: deep molecular response; TKI: tyrosine kinase inhibitor
.
.
p: level of significance between AYA and the elderly group
.
MMR: major molecular response; DMR: deep molecular response; TKI: tyrosine kinase inhibitor
.
Figure 2: Responses to TKIs by age group
.
(A) Cumulative incidence of MMR
.
(B) Cumulative incidence of DMR
.
p indicates the significance level between AYA and the elderly group
.
MMR: major molecular response; DMR: deep molecular response; TKI: tyrosine kinase inhibitor
.
(A) Cumulative incidence of MMR
.
(B) Cumulative incidence of DMR
.
p indicates the significance level between AYA and the elderly group
.
MMR: major molecular response; DMR: deep molecular response; TKI: tyrosine kinase inhibitor
In AYA patients, peripheral blood (PB) white blood cell counts and percentage of blasts were significantly elevated at diagnosis, hemoglobin levels were lower, and spleens were larger
.
Figure 3: Cumulative incidence of conversion to AP or BP by age group
Figure 3: Cumulative incidence of conversion to AP or BP by age groupFigure 4: Long-term outcomes of patients treated with TKIs by age group
Figure 4: Long-term outcomes of patients treated with TKIs by age group
Figure 5: Molecular responses to each TKI, grouped by age
Figure 5: Molecular responses to each TKI, grouped by age
In conclusion, AYA patients had a higher tumor burden at the time of diagnosis of CML-CP, but their prognosis was not poor compared with older patients treated with TKIs
Original source:
Original source:Nishiyama-Fujita Y, Nakazato T, Iriyama N, Tokuhira M, Ishikawa M, Sato E, Takaku T, Sugimoto K, Fujita H, Fujioka I, Tsuchiya S, Kimura Y, Iwanaga E, Komatsu N, Asou N, Kizaki M, Hatta Y, Kawaguchi T.
Nishiyama-Fujita Y, Nakazato T, Iriyama N, Tokuhira M, Ishikawa M, Sato E, Takaku T, Sugimoto K, Fujita H, Fujioka I, Tsuchiya S, Kimura Y, Iwanaga E, Komatsu N, Asou N, Kizaki M, Hatta Y, Kawaguchi T.
Outcomes of adolescents and young adults with chronic-phase chronic myeloid leukaemia treated with tyrosine kinase inhibitors.
Ann Med.
2022 Dec;54(1):1244-1254.
doi: 10.
1080/07853890.
2022.
2069280.
PMID: 35486442.
Nishiyama-Fujita Y, Nakazato T, Iriyama N, Tokuhira M, Ishikawa M, Sato E, Takaku T, Sugimoto K, Fujita H, Fujioka I, Tsuchiya S, Kimura Y, Iwanaga E, Komatsu N, Asou N, Kizaki M, Hatta Y, Kawaguchi T.
Outcomes of adolescents and young adults with chronic-phase chronic myeloid leukaemia treated with tyrosine kinase inhibitors.
Ann Med.
2022 Dec;54(1):1244-1254.
doi: 10.
1080/07853890.
2022.
2069280.
PMID: 35486442.
leave a message here
